Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243628 · ClinicalTrials.gov registry record · Phase 4
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A Phase 4 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT05243628 is a Phase 4 study that has completed, run by Mannkind Corporation. The registered enrollment target is 33 participants.
The verdict
NCT05243628, a Phase 4 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
Interventions
- BIOLOGICAL insulin degludec
- BIOLOGICAL Afrezza (insulin human) Inhalation Powder
- DEVICE Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05243628
The ClinicalTrials.gov registry entry for NCT05243628 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin degludec is the first listed.
NCT05243628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05243628 about?
NCT05243628 is a clinical study titled "Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes". A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
What is the current status of trial NCT05243628?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2022-03-31. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT05243628?
The interventions under investigation include: insulin degludec (BIOLOGICAL), Afrezza (insulin human) Inhalation Powder (BIOLOGICAL), Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID) (DEVICE).
Who is sponsoring clinical trial NCT05243628?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.